Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) produced a 27.32% rally since recording the worst price of $1.94. Thanks to the latest -2.37% decrease, it now trades at $2.47. Throughout the trading on Jul. 14, 2017, the share price floated between $2.46 and $2.55. This company shares are 159.11% off its target price of $6.4 and the current market capitalization stands at $306.87M. The recent change has given its price a -4.31% deficit over SMA 50 and -43.61% deficit over its 52-week high. The stock witnessed -5.36% declines, -21.84% declines and 2.07% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found RIGL’s volatility during a week at 4.88% and during a month it has been found around 5.32%.

Rigel Pharmaceuticals, Inc. (RIGL) Top Holders

Institutional investors currently hold around $275 million or 90.4% in RIGL stock. Look at its top three institutional owners. Fmr Llc owns $46.39 million in Rigel Pharmaceuticals, Inc., which represents roughly 15.12% of the company’s market cap and approximately 16.87% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 13,843,629 shares of the stock are valued at $35.02 million. The third largest holder is Blackrock Inc., which currently holds $25.72 million worth of this stock and that ownership represents nearly 8.38% of its market capitalization.

Rigel Pharmaceuticals, Inc. 13F Filings

At the end of March 2017 reporting period, 53 institutional holders increased their position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by some 28,582,215 shares, 44 decreased positions by 8,556,580 and 20 held positions by 71,399,858. That puts total institutional holdings at 108,538,653 shares, according to SEC filings. The stock grabbed 15 new institutional investments totaling 12,709,792 shares while 15 institutional investors sold out their entire positions totaling 1,444,378 shares.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Insider Trades

Multiple company employees have indulged in significant insider trading. Rigel Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Medical Officer Duliege Anne-Marie has sold 5,000 shares of Rigel Pharmaceuticals, Inc. (RIGL) in trading session dated Jul. 05, 2017. These shares are worth $13,450 and were traded at $2.69 each. The SEC filing shows that Duliege Anne-Marie performed a sale of 5,000 shares. The Chief Medical Officer disposed these shares by way of transaction on Jan. 03, 2017. The company’s shares were given away at $2.41 per share worth to an income of some $12,050 on account of Duliege Anne-Marie.

EVP, Pres. Discovery&Research, PAYAN DONALD G, sold 5,303 common shares of Rigel Pharmaceuticals, Inc. (RIGL) in the open market. In a transaction dated Aug. 30, 2016, the shares were put up for sale at an average price of $4, raking in a sum of $21,212. After this sale, 53,031 common shares of RIGL are directly owned by the insider, with total stake valued at $130,987.

In the transaction dated Jun. 10, 2015, the great number of shares disposed came courtesy the EVP, Pres. Discovery&Research; PAYAN DONALD G disposed a total of 41,666 shares at an average price of $3.68, amounting to approximately $153,331. The insider now directly owns 58,334 shares worth $144,085.

Rigel Pharmaceuticals, Inc. (RIGL) Analyst Guide

Several analysts have released their opinion on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.